Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha2-Adrenoreceptor antagonists.

P Mayer1, T Imbert

  • 1Centre de Recherche Pierre Fabre, Division de Chimie Medicinale III, 17 avenue Jean Moulin, F 81106, Castres, Cedex 06, France. patrice.mayer@pierre-fabre.com

Idrugs : the Investigational Drugs Journal
|July 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the aquatic toxicity and environmental safety of tracer compounds Rhodamine B and Rhodamine WT.

Water research·2021
Same author

Radiological evaluation of pancreatic cancer: What is the significance of arterial encasement >180° after neoadjuvant treatment?

European journal of radiology·2021
Same author

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Blood·2020
Same author

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Leukemia·2020
Same author

Evaluation of the inflammatory markers CCL8, CXCL5, and LIF in patients with anastomotic leakage after colorectal cancer surgery.

International journal of colorectal disease·2020
Same author

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Leukemia·2020
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Alpha2-adrenoceptor antagonists, studied since the 1970s, show renewed therapeutic potential. Research highlights new applications in neurodegenerative disorders, obesity, and schizophrenia.

Area of Science:

  • Pharmacology
  • Neuroscience

Background:

  • Alpha2-adrenoceptor antagonists have been researched for various therapeutic uses since the 1970s.
  • Recent advancements include distinguishing alpha2-adrenoceptor subtypes.

Purpose of the Study:

  • To review the literature on the therapeutic potential of alpha2-adrenoceptor antagonists from 1990-2000.
  • To highlight emerging applications of these agents.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of studies published between 1990 and 2000.

Main Results:

  • Interest in alpha2-adrenoceptor antagonists has been revitalized.
  • Emerging evidence supports applications in Alzheimer's, Parkinson's, obesity, and schizophrenia.

Related Experiment Videos

Conclusions:

  • Alpha2-adrenoceptor antagonists represent a promising class of agents.
  • Further research into subtype-specific antagonists may yield novel treatments.